Entero Healthcare Solutions Ltd
NSE:ENTERO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its Industry Average (83), the stock would be worth ₹0 (100% downside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0 | ₹1 216.4 |
0%
|
| Industry Average | 83 | ₹0 |
-100%
|
| Country Average | 49.7 | ₹0 |
-100%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
E
|
Entero Healthcare Solutions Ltd
NSE:ENTERO
|
52.9B INR | 0 | 0 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
100.1B USD | 12.5 | 23.1 | |
| US |
|
Cencora Inc
NYSE:COR
|
59.1B USD | 19.7 | 36.4 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
59.5B USD | 19.8 | 36.6 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
46.1B USD | 6.8 | 27.7 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
32.3B AUD | 40.9 | 35.5 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
63.4B CNY | 21.6 | 11.1 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
8.6B USD | 8.9 | 21.5 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
58.5B CNY | 136.2 | 20.6 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | -236.8 | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
57.6B HKD | -35.6 | 7.2 |
Market Distribution
Other Multiples
Entero Healthcare Solutions Ltd
Glance View
Entero Healthcare Solutions Ltd is a IN-based company operating in Health Care Providers & Services industry. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2024-02-16. Entero Healthcare Solutions Limited is an India-based technology-driven and integrated healthcare products distribution company. The company offers a range of pharmaceuticals and other healthcare products to approximately 81,400 retail pharmacies and healthcare practitioners. Its portfolio includes 64500+ SKUs from approximately 1900 pharma companies. The company is a supplier for approximately 3,400 hospitals across India, including corporate hospital chains. The company sells private label products under its private label, Entero Surgicals. The company offers both demand generation and demand fulfilment solutions to healthcare product manufacturers. The company has approximately 73 distribution warehouses located across 37 cities in 19 states and union territories, developed 424,028 square feet of warehousing space with temperature monitoring systems and modern storage solutions. Its Entero Direct platform is a cloud-based software-as-a-service solution that allows retailers to order their procurement needs from the Company.
